Last reviewed · How we verify
ARGX-110
At a glance
| Generic name | ARGX-110 |
|---|---|
| Also known as | Cusatuzumab, JNJ-74494550 |
| Sponsor | OncoVerity, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (PHASE2)
- Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (PHASE1)
- A Study of ARGX-110 in Participants With Advanced Malignancies (PHASE1, PHASE2)
- A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) (PHASE1, PHASE2)
- A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment (PHASE1)
- A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) (PHASE2)
- A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARGX-110 CI brief — competitive landscape report
- ARGX-110 updates RSS · CI watch RSS
- OncoVerity, Inc. portfolio CI